Publications by authors named "O Levrel"
Article Synopsis
- - The study analyzed characteristics, treatment approaches, and outcomes of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) in 1,075 patients over 12 years, noting significant differences and similarities between the two cancers.
- - Findings indicated that HCC patients generally presented with earlier-stage disease and had a higher prevalence of cirrhosis (89%), while iCCA patients were more likely to be female and had fewer cirrhosis cases (34%).
- - Overall survival rates revealed HCC patients lived longer (18.4 months) compared to iCCA patients (7.0 months), with specific molecular alterations found in half of the iCCA cases, highlighting potential new treatment
Background: Bladder cancer (BCa) is more common in men and presents differences in molecular subtypes based on sex. Fibroblast growth factor receptor 3 (FGFR3) mutations are enriched in the luminal papillary muscle-invasive BCa (MIBC) and non-MIBC subtypes.
Objective: To determine whether FGFR3 mutations initiate BCa and impact BCa male sex bias.
Specific germline activating point mutations in the gene encoding the tyrosine kinase receptor FGFR3 (fibroblast growth factor receptor 3) result in autosomal dominant human skeletal dysplasias. The identification in multiple myeloma and in two epithelial cancers-bladder and cervical carcinomas-of somatic FGFR3 mutations identical to the germinal activating mutations found in skeletal dysplasias, together with functional studies, have suggested an oncogenic role for this receptor. Although acanthosis nigricans, a benign skin tumor, has been found in some syndromes associated with germinal activating mutations of FGFR3, the role of activated FGFR3 in the epidermis has never been investigated.
View Article and Find Full Text PDFFrequent activating mutations of FGFR3 (fibroblast growth factor receptor 3) are found in human urothelial cell carcinomas, particularly in superficial papillary tumours (in 74%-84% of pTaG1-G2), but not in carcinomas in situ (CIS) and at a low rate in invasive tumours (in 16%-21% of pT1-4). In mice and rats, BBN (N-butyl-N-(4-hydroxybutyl)nitrosamine) specifically induces bladder tumours. In rats, superficial papillary tumours are mostly observed.
View Article and Find Full Text PDFBackground: Despite numerous studies, no biological marker has been identified that accurately predicts prognosis of advanced ovarian cancer. Tumors from a homogeneous population of 117 patients with a stage III/IV ovarian cancer, enrolled in a multicenter prospective GINECO clinical trial were analyzed retrospectively.
Patients And Methods: All patients received the same platinum-based combination therapy and were followed-up for a median of 68 months.